Form 4: Aileron Therapeutics Director William Fairey Granted Stock Options

Director William Fairey of Aileron Therapeutics was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.

Summary

• William Fairey, a director at Aileron Therapeutics, was granted 35,000 stock options on December 2, 2024.
• The exercise price of these options is $2.85 per share.
• The options will vest in full on December 2, 2025.
• The options expire on December 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options to a director aligns their interests with the company's performance and shareholder value.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with the company's success.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry, similar to companies like Amgen, Biogen, and Gilead Sciences.
• The vesting period of one year is also typical, aligning with industry norms for incentivizing long-term performance.
• The exercise price of $2.85 is specific to Aileron's stock price and market conditions at the time of the grant.

Stakeholder Impact

• The stock option grant may positively impact shareholder sentiment by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, Aileron Therapeutics, equity, vesting, ALRN